OncoZenge AB (publ) (STO:ONCOZ)

Sweden flag Sweden · Delayed Price · Currency is SEK
5.90
-0.22 (-3.59%)
Aug 6, 2025, 4:29 PM CET
-3.59%
Market Cap74.62M
Revenue (ttm)2.71M
Net Income (ttm)-6.27M
Shares Out12.65M
EPS (ttm)-0.54
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume30,312
Average Volume69,741
Open6.20
Previous Close6.12
Day's Range5.57 - 6.27
52-Week Range3.15 - 12.10
Beta1.44
RSI43.43
Earnings DateAug 8, 2025

About OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 1
Stock Exchange Nasdaq Stockholm
Ticker Symbol ONCOZ
Full Company Profile

Financial Performance

In 2024, OncoZenge AB's revenue was 1,000, a decrease of -66.67% compared to the previous year's 3,000. Losses were -8.69 million, -45.37% less than in 2023.

Financial Statements

News

There is no news available yet.